Tapinarof not checked

Organon and Co · DMVT-505 · OG-0505

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
1 active
10 in total
Targets
 

What this is

How it works
Aryl Hydrocarbon Receptor Agonist FDA class
How it’s given
“Tapinarof cream, 1%: Applied topically once daily to lesions on participant's skin during the Double-Blind period. During the Open-Label Period, it will be applied once daily to lesions, as needed.”In the company’s words, NCT07265479 on ClinicalTrials.gov
Tested for
Atopic Dermatitis
Main trialPhase 3
“The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.”In the company’s words, NCT07265479 on ClinicalTrials.gov
Other names
DMVT-505 · OG-0505 · GSK2894512A · GSK28994512 · STI-1001 · WBI-1001

Other drugs for Atopic Dermatitis

All 90 drugs for Atopic Dermatitis

Copies tested against it2

Other companies’ versions, mostly cheaper copies for when the patent ends

Coming up1

Changes1

Last 90 days

Trials10

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Aug 2027 A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
Phase 3Completed 13 May 2020 Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)
Phase 3Completed 26 May 2020 Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)
Phase 3Completed 6 Apr 2021 Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)
Phase 3Completed 3 Feb 2023 Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)
Phase 3Completed 30 Mar 2023 Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults
Phase 3Completed 29 Feb 2024 Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis
Phase 3Completed 14 Oct 2026 Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
Phase 2Completed 9 Jan 2020 Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
Phase 2Completed 24 Aug 2022 Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Tapinarof

Following is part of Solo: you see every change to Tapinarof the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in